|
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
|
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
GWASDB |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.
|
30098506 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CtBP2 is overexpressed in GC and may accelerate GC tumorigenesis and metastasis, which could represent an independent prognostic marker and promising therapeutic target for GC.
|
28404932 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Overexpression of C-terminal binding protein-2 (CtBP2) has been noted to correlate with cancer metastasis in several human cancers including breast cancer.
|
24522810 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2) enhances cancer proliferation and metastasis.
|
28412731 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrate that CtBP1 and CtBP2 both have p53-dependent and -independent roles in suppressing the sensitivity of breast cancer cells to mechanistically diverse cancer chemotherapeutic agents.
|
20964627 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although its functions remain to be clarified in PCa cells, HNF1β and CtBP2 are associated with cancer cell proliferation, tumor progression, and castration-resistant disease.
|
24332637 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
MDSCs triggered miRNA101 expression in cancer cells. miRNA101 subsequently repressesed the corepressor gene C-terminal binding protein-2 (CtBP2), and CtBP2 directly targeted stem cell core genes resulting in increased cancer cell stemness and increasing metastatic and tumorigenic potential.
|
24012420 |
2013 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
ERalpha expression highly correlates with ZNF217 in lysates from breast tumors (n = 15), and ERalpha co-precipitates ZNF217 and its binding partner CtBP2 from nuclear extracts.
|
24962896 |
2014 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
We postulate that RIBEYE disruption is partially compensated by multi-AZ organization.
|
29328020 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
|
Neoplasm Invasiveness
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.
|
28414304 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of both CtBP2 and p16INK4A were significantly related to histological differentiation (P < 0.01 and P = 0.004, respectively) and metastasis (P = 0.046 and 0.047, respectively).
|
28412731 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Our data revealed that the expression of CtBP1, but not CTBP2, was upregulated in 102 GC tissue samples compared with 98 noncancerous tissue samples, and the elevated expression level of CtBP1 was notably associated with distant metastasis.
|
31308691 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of this study was to examine the effect of cyclase-associated protein 1 (CAP1) overexpression on CtBP2 expression and related mechanism in the metastasis of breast cancer.
|
24522810 |
2014 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, CtBP2 is overexpressed in GC and may accelerate GC tumorigenesis and metastasis, which could represent an independent prognostic marker and promising therapeutic target for GC.
|
28404932 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The results revealed that the expression of CtBP2, but not CtBP1, was upregulated in OS tissue samples and the elevated expression level of CtBP2 was notably associated with distant metastasis.
|
31214864 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression.
|
25820824 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As CtBP2 is targetable by an inhibitor of its dehydrogenase domain, understanding CtBP2's role in adenoma formation is necessary to optimize CtBP-targeted therapies in <i>Apc</i> mutated human neoplasia.
|
30197752 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that CtBP2 was overexpressed in GC tissues and closely correlated with poor differentiation, advanced tumor stage and poor prognosis in GC patients.
|
28404932 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A small-molecule inhibitor of CtBP2, 4-chloro-hydroxyimino phenylpyruvate (4-Cl-HIPP) phenocopied Ctbp2 deletion, decreasing tumor burden similarly to gemcitabine, and the combination of 4-Cl-HIPP and gemcitabine further synergistically suppressed tumor growth.
|
31586042 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells.
|
25820824 |
2015 |